title: Role of alpha2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental factor?
abstract: alpha2-Macroglobulin (alpha2M) has been identified as a carrier protein for beta-amyloid (Abeta) decreasing fibril formation and affecting the neurotoxicity of this peptide. The alpha2-macroglobulin receptor/low density lipoprotein receptor related protein (LRP) is involved in the internalization and degradation of the alpha2M/Abeta complexes and its impairment has been reported to occur in Alzheimer's disease. Previous studies have shown alpha2M to determine an enhancement or a reduction of Abeta toxicity in different culture systems. In order to clarify the role of alpha2M in Abeta neurotoxicity, we challenged human neuroblastoma cell lines with activated alpha2M in combination with Abeta. Our results show that in neuroblastoma cells expressing high levels of LRP, the administration of activated alpha2M protects the cells from Abeta neurotoxicity. Conversely, when this receptor is not present alpha2M determines an increase in Abeta toxicity as evaluated by MTT and TUNEL assays. In LRP-negative cells transfected with the full-length human LRP, the addition of activated alpha2M resulted to be protective against Abeta-induced neurotoxicity. By means of recombinant proteins we ascribed the neurotoxic activity of alpha2M to its FP3 fragment which has been previously shown to bind and neutralize transforming growth factor-beta. These studies provide evidence for both a neuroprotective and neurotoxic role of alpha2M regulated by the expression of its receptor LRP.
authors.affiliation: Department of Biology, University 'Roma Tre', Rome, Italy. fabrizi@uniroma3.it
authors.forename: C
authors.initials: C
authors.lastname: Fabrizi
authors.forename: R
authors.initials: R
authors.lastname: Businaro
authors.forename: G M
authors.initials: GM
authors.lastname: Lauro
authors.forename: L
authors.initials: L
authors.lastname: Fumagalli
mesh_terms: D016229:Amyloid beta-Peptides / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D020287:In Situ Nick-End Labeling; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D008744:Methylamines / Q000494:pharmacology; D009447:Neuroblastoma; D009498:Neurotoxins / Q000633:toxicity; D010446:Peptide Fragments / Q000633:toxicity; D011971:Receptors, Immunologic / Q000235:genetics / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D014162:Transfection; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D000511:alpha-Macroglobulins / Q000737:chemistry / Q000494:pharmacology* / Q000502:physiology
chemical_list: D016229:Amyloid beta-Peptides; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D008744:Methylamines; D009498:Neurotoxins; D010446:Peptide Fragments; D011971:Receptors, Immunologic; D011993:Recombinant Fusion Proteins; D016212:Transforming Growth Factor beta; D000511:alpha-Macroglobulins; C027451:methylamine